Yehia I. Abugabal
The University of Texas MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Cancer, Hypoxia, and Metabolism, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma(2021)80 cited
- → Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade(2020)75 cited
- → Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study(2022)68 cited
- → Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice(2021)63 cited
- → Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma(2021)61 cited
- → Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study(2020)59 cited
- → Origin and role of hepatic myofibroblasts in hepatocellular carcinoma(2020)39 cited
- → Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy(2020)35 cited
- → Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.(2020)28 cited
- → A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma(2023)22 cited